BKNG three-lens brief
Evidence-based stock research on BKNG. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Analyst mean target $215.66 — 35% above current (35 analysts).
- Reported earnings on 2026-11-03.
BKNG closed at $160.21 (+0.60%) as of 2026-11-12. Market cap: $119.15B. P/E (trailing) 17.4. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $215.66 — 35% above current (35 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $8.89B, net income $2.72B, free cash flow $7.61B.
Why three lenses on BKNG, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BKNG across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BKNG" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BKNG brief"></iframe>